Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M.

Liver Cancer. 2019 May;8(3):203-217. doi: 10.1159/000489833. Epub 2018 Jun 22.

2.

Endoscopic biliary drainage in patients with cholangiocarcinoma - self-expanding metal versus polyethylene stents.

Voigtländer T, Schweitzer N, von Hahn T, Manns MP, Vogel A, Kirstein MM.

Scand J Gastroenterol. 2019 May;54(5):640-645. doi: 10.1080/00365521.2019.1614661. Epub 2019 May 24.

PMID:
31122083
3.

Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter.

Dewald CLA, Meine TC, Winther HMB, Kloeckner R, Maschke SK, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Renne J, Hinrichs JB.

Cardiovasc Intervent Radiol. 2019 May 14. doi: 10.1007/s00270-019-02243-4. [Epub ahead of print]

PMID:
31089781
4.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M.

Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.

5.

Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.

Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, Vogel A.

Liver Int. 2019 May;39(5):914-923. doi: 10.1111/liv.14063. Epub 2019 Mar 18.

PMID:
30716200
6.

Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.

Schulte L, Scheiner B, Voigtländer T, Koch S, Schweitzer N, Marhenke S, Ivanyi P, Manns MP, Rodt T, Hinrichs JB, Weinmann A, Pinter M, Vogel A, Kirstein MM.

Liver Int. 2019 Apr;39(4):714-726. doi: 10.1111/liv.14048. Epub 2019 Feb 7.

PMID:
30663219
7.

Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.

Alharbi AF, Kratzke RA, D'Cunha J, Maddaus MA, Sanghavi K, Kirstein MN.

Cancer Chemother Pharmacol. 2019 Feb;83(2):387-391. doi: 10.1007/s00280-018-3757-7. Epub 2018 Dec 12.

PMID:
30542769
8.

Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis.

Taubert R, Diestelhorst J, Junge N, Kirstein MM, Pischke S, Vogel A, Bantel H, Baumann U, Manns MP, Wedemeyer H, Jaeckel E.

Sci Rep. 2018 Nov 28;8(1):17452. doi: 10.1038/s41598-018-35882-7.

9.

Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.

Kirchner T, Marquardt S, Werncke T, Kirstein MM, Brunkhorst T, Wacker F, Vogel A, Rodt T.

Abdom Radiol (NY). 2019 Apr;44(4):1554-1561. doi: 10.1007/s00261-018-1802-y.

PMID:
30311050
10.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

11.

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.

Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W, Radeleff B, Trillaud H, Tselikas L, Vicente E, Wiggermann P, Manns MP, Vogel A, Wacker FK.

Eur Radiol. 2019 Apr;29(4):1882-1892. doi: 10.1007/s00330-018-5729-z. Epub 2018 Sep 25.

PMID:
30255257
12.

Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC.

Hartrumpf KJ, Marquardt S, Werncke T, Murray T, Kirstein MM, Vogel A, Wacker F, Rodt T.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1991-1999. doi: 10.1007/s00432-018-2704-7. Epub 2018 Jul 14.

PMID:
30008024
13.

Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis.

Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J.

Am J Gastroenterol. 2018 Jul;113(7):1099. doi: 10.1038/s41395-018-0118-4.

PMID:
29895985
14.

Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE.

Nörthen A, Asendorf T, Shin HO, Hinrichs JB, Werncke T, Vogel A, Kirstein MM, Wacker FK, Rodt T.

Abdom Radiol (NY). 2018 Dec;43(12):3288-3300. doi: 10.1007/s00261-018-1610-4. Review.

PMID:
29680967
15.

Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.

Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J.

Am J Gastroenterol. 2018 Oct;113(10):1475-1483. doi: 10.1038/s41395-018-0041-8. Epub 2018 Mar 13. Erratum in: Am J Gastroenterol. 2018 Jul;113(7):1099.

PMID:
29535416
16.

Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.

Kirstein MM, Voigtländer T, Schweitzer N, Hinrichs JB, Marquardt J, Wörns MA, Kloeckner R, Fründt TW, Ittrich H, Wacker F, Rodt T, Manns MP, Wege H, Weinmann A, Vogel A.

United European Gastroenterol J. 2018 Mar;6(2):238-246. doi: 10.1177/2050640617716597. Epub 2017 Jun 20.

17.

Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction: quantitative assessment of flow and perfusion changes using 2D-perfusion angiography following shunt revision.

Maschke SK, Werncke T, Renne J, Kloeckner R, Marquardt S, Kirstein MM, Potthoff A, Wacker FK, Meyer BC, Hinrichs JB.

Abdom Radiol (NY). 2018 Oct;43(10):2868-2875. doi: 10.1007/s00261-018-1547-7.

PMID:
29500653
18.

Percutaneous endoscopic gastrostomy with and without jejunal extension in patients with amyotrophic lateral sclerosis.

Kirstein MM, Körner S, Schneider A, Manns MP, Petri S, Voigtländer T.

Eur J Gastroenterol Hepatol. 2018 Mar;30(3):257-262. doi: 10.1097/MEG.0000000000001054.

PMID:
29324589
19.

Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma - a case-control study.

Kirstein MM, Voigtländer T, Schweitzer N, Gebel M, Hinrichs JB, Rodt T, Manns MP, Wacker F, Potthoff A, Vogel A.

Scand J Gastroenterol. 2017 Dec;52(12):1398-1406. doi: 10.1080/00365521.2017.1370008. Epub 2017 Aug 28.

PMID:
28847187
20.

Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.

Maschke SK, Werncke T, Klöckner R, Rodt T, Renne J, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Hinrichs JB.

Abdom Radiol (NY). 2018 May;43(5):1245-1253. doi: 10.1007/s00261-017-1296-z.

PMID:
28840307
21.

Cyclin-Dependent Kinase 4 Regulates Adult Neural Stem Cell Proliferation and Differentiation in Response to Insulin.

Chirivella L, Kirstein M, Ferrón SR, Domingo-Muelas A, Durupt FC, Acosta-Umanzor C, Cano-Jaimez M, Pérez-Sánchez F, Barbacid M, Ortega S, Burks DJ, Fariñas I.

Stem Cells. 2017 Dec;35(12):2403-2416. doi: 10.1002/stem.2694. Epub 2017 Sep 3.

22.

Risk estimation for biliary tract cancer: Development and validation of a prognostic score.

Schweitzer N, Fischer M, Kirstein MM, Berhane S, Kottas M, Sinn M, Gonzalez-Carmona MA, Balta Z, Weismüller TJ, Strassburg CP, Reineke-Plaaß T, Bektas H, Manns MP, Johnson P, Weinmann A, Vogel A.

Liver Int. 2017 Dec;37(12):1852-1860. doi: 10.1111/liv.13517. Epub 2017 Jul 28.

PMID:
28695669
23.

Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.

Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP, Wacker F, Vogel A.

J Cancer Res Clin Oncol. 2017 Oct;143(10):2113-2121. doi: 10.1007/s00432-017-2461-z. Epub 2017 Jun 20.

PMID:
28634727
24.

Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization.

Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T.

Cardiovasc Intervent Radiol. 2017 Oct;40(10):1559-1566. doi: 10.1007/s00270-017-1681-6. Epub 2017 May 9.

PMID:
28488104
25.

The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.

Schweitzer N, Weber T, Kirstein MM, Fischer M, Kratzel AM, Reineke-Plaaß T, Lehner F, Manns MP, Vogel A.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1347-1355. doi: 10.1007/s00432-017-2392-8. Epub 2017 Mar 17.

PMID:
28314929
26.

Clinical Impact of Liver Biopsies in Liver Transplant Recipients.

Voigtländer T, Alten TA, Kirstein MM, Lehner F, Manns MP, Schlué J, Wedemeyer H, Lankisch TO.

Ann Transplant. 2017 Feb 24;22:108-114.

27.

Epidemiology and Risk Factors of Cholangiocarcinoma.

Kirstein MM, Vogel A.

Visc Med. 2016 Dec;32(6):395-400. doi: 10.1159/000453013. Epub 2016 Dec 1. Erratum in: Visc Med. 2017 Jun;33(3):226.

28.

Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center.

Kirstein MM, Schweitzer N, Winter T, Lappas K, Graen N, Kunstmann I, Voigtländer T, Reineke-Plaaß T, Manns MP, Lehner F, Rodt T, Vogel A.

J Gastroenterol Hepatol. 2017 Oct;32(10):1730-1738. doi: 10.1111/jgh.13761.

PMID:
28185302
29.

Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.

Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ.

Br J Cancer. 2017 Feb 14;116(4):448-454. doi: 10.1038/bjc.2016.423. Epub 2017 Jan 26.

30.

Transarterial Chemoembolization versus Resection in Patients with Large, Solitary Hepatocellular Carcinoma.

Kirstein MM, Vogel A.

J Vasc Interv Radiol. 2016 Nov;27(11):1773-1774. doi: 10.1016/j.jvir.2015.10.027. No abstract available.

PMID:
27926422
31.

Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors' reply.

Bantel H, Wandrer F, Bock B, Kirstein MM, Schulze-Osthoff K.

Aliment Pharmacol Ther. 2017 Jan;45(1):184-185. doi: 10.1111/apt.13826. No abstract available.

32.

Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization.

Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtländer T, Wacker F, Manns MP, Rodt T, Vogel A.

Scand J Gastroenterol. 2017 Jan;52(1):116-124. doi: 10.1080/00365521.2016.1233579. Epub 2016 Sep 22.

PMID:
27598949
33.

Erratum: Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).

Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, Lerner RE.

Breast Cancer Res Treat. 2016 Jun;157(2):403. doi: 10.1007/s10549-016-3818-8. No abstract available.

PMID:
27167985
34.

Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Liang S, Brundage RC, Jacobson PA, Blaes A, Kirstein MN.

Br J Clin Pharmacol. 2016 Sep;82(3):773-83. doi: 10.1111/bcp.12989. Epub 2016 Jun 3.

35.

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA.

Transl Res. 2016 Sep;175:103-115.e4. doi: 10.1016/j.trsl.2016.03.017. Epub 2016 Mar 31.

36.

Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).

Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, Lerner RE.

Breast Cancer Res Treat. 2016 Feb;155(3):501-12. doi: 10.1007/s10549-016-3710-6. Epub 2016 Feb 11. Erratum in: Breast Cancer Res Treat. 2016 Jun;157(2):403.

37.

Prediction of short- and long-term outcome in patients with autoimmune hepatitis.

Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP, Vogel A.

Hepatology. 2015 Nov;62(5):1524-35. doi: 10.1002/hep.27983. Epub 2015 Aug 25.

PMID:
26178791
38.

Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.

Kirstein MM, Schweitzer N, Schmidt S, Klöpper A, Ringe KI, Lehmann U, Manns MP, Wedemeyer H, Vogel A.

Acta Gastroenterol Belg. 2014 Dec;77(4):386-8.

PMID:
25682626
39.

Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.

Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A.

Oncologist. 2014 Nov;19(11):1156-68. doi: 10.1634/theoncologist.2014-0032. Epub 2014 Oct 17.

40.

[RAS testing in metastatic colorectal cancer].

Kirstein MM, Vogel A.

Z Gastroenterol. 2014 Sep;52(9):1095-6. doi: 10.1055/s-0034-1384878. Epub 2014 Sep 8. German. No abstract available.

PMID:
25198090
41.

The pathogenesis of hepatocellular carcinoma.

Kirstein MM, Vogel A.

Dig Dis. 2014;32(5):545-53. doi: 10.1159/000360499. Epub 2014 Jul 14. Review.

PMID:
25034287
42.

MT5-MMP regulates adult neural stem cell functional quiescence through the cleavage of N-cadherin.

Porlan E, Martí-Prado B, Morante-Redolat JM, Consiglio A, Delgado AC, Kypta R, López-Otín C, Kirstein M, Fariñas I.

Nat Cell Biol. 2014 Jul;16(7):629-38. doi: 10.1038/ncb2993. Epub 2014 Jun 22.

PMID:
24952463
43.

[Aspirin and PIK3CA mutation in colorectal cancer].

Kirstein MM, Vogel A.

Z Gastroenterol. 2014 Mar;52(3):306-7. doi: 10.1055/s-0033-1356386. Epub 2014 Mar 12. German. No abstract available.

PMID:
24622874
44.

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN.

Br J Cancer. 2014 Jan 21;110(2):304-12. doi: 10.1038/bjc.2013.738. Epub 2013 Dec 3.

45.

A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer.

Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg JM.

Eur J Cancer. 2014 Jan;50(1):40-9. doi: 10.1016/j.ejca.2013.08.008. Epub 2013 Sep 4. Review.

PMID:
24011538
46.

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.

Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.

Liver Int. 2013 May;33(5):780-93. doi: 10.1111/liv.12126. Epub 2013 Mar 15.

PMID:
23489999
47.

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK.

Pharmacogenomics. 2012 Jul;13(9):1009-21. doi: 10.2217/pgs.12.81.

PMID:
22838949
48.

IRS2 signalling is required for the development of a subset of sensory spinal neurons.

Chirivella L, Cano-Jaimez M, Pérez-Sánchez F, Herraez L, Carretero J, Fariñas I, Burks DJ, Kirstein M.

Eur J Neurosci. 2012 Feb;35(3):341-52. doi: 10.1111/j.1460-9568.2011.07959.x.

PMID:
22288475
49.

Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.

Jensen K, Johnson LA, Jacobson PA, Kachler S, Kirstein MN, Lamba J, Klotz KN.

Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):519-25. doi: 10.1007/s00210-011-0719-6. Epub 2012 Jan 17.

50.

Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.

Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN.

AAPS J. 2012 Mar;14(1):1-9. doi: 10.1208/s12248-011-9308-3. Epub 2011 Nov 19.

Supplemental Content

Loading ...
Support Center